Zobrazeno 1 - 10
of 25
pro vyhledávání: '"Scott M, Hynes"'
Autor:
Kenneth C. Cassidy, Christopher D. Payne, Scott M. Hynes, Enaksha R Wickremsinhe, Yingying Guo
Publikováno v:
Xenobiotica. 50:793-804
The disposition and metabolism of prexasertib, a CHK-1 inhibitor was characterised over a 120 h period following a single 170-mg intravenous dose of [14C]prexasertib (50 µCi) to 6 patients with adv...
Autor:
Xuejing Wang, Katherine M Bell-McGuinn, Jimmy Hwang, Johanna C. Bendell, Hans Christian Reinhardt, Daphne L. Farrington, Celine Pitou, Helge Bischoff, Robert M. Campbell, Thomas Zander, Scott M. Hynes, Philip W. Iversen, Michael Thomas
Publikováno v:
Investigational New Drugs. 38:1145-1155
Purpose The primary objective was to determine the recommended Phase 2 dose (RP2D) of checkpoint kinase 1 inhibitor, prexasertib, in combination with the p38 mitogen-activated protein kinase inhibitor, ralimetinib, which may be safely administered to
Autor:
Adam Abel, Alejandro Navarro, Lauren Averett Byers, Irfan Cicin, Mustafa Ozguroglu, Ji-Youn Han, Aimee Bence Lin, Samuel McNeely, Xuejing Wang, Melissa Lynne Johnson, Konstantin H. Dragnev, Scott M. Hynes, Eric Scott Schaefer, Igor Bondarenko, Martin Forster
Publikováno v:
Scientia
Background: This study assessed the checkpoint kinase 1 inhibitor prexasertib in patients with extensive-stage small-cell lung cancer (ED-SCLC). Patients and Methods: This was a parallel-cohort phase II study of 105 mg/m2 prexasertib once every 14 da
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ed4c18fc47f726ad124316f502641acd
https://hdl.handle.net/11351/7780
https://hdl.handle.net/11351/7780
Autor:
Enaksha R, Wickremsinhe, Scott M, Hynes, Christopher D, Payne, Yingying, Guo, Kenneth C, Cassidy
Publikováno v:
Xenobiotica; the fate of foreign compounds in biological systems. 50(7)
The disposition and metabolism of prexasertib, a CHK-1 inhibitor was characterised over a 120 h period following a single 170-mg intravenous dose of [
Autor:
Scott M. Hynes, S. Muralidhar Beeram, Siqing Fu, Aimee Bence Lin, Wei Zhang, Michael S. Gordon, Frank Tsai, Filip Janku, Amita Patnaik, Kyri Papadopoulous, Melinda D. Willard, David S. Hong, Sushma R. Gundala, Drew W. Rasco
Publikováno v:
Cancer Chemotherapy and Pharmacology. 82:407-418
The phase I study characterized the safety, pharmacokinetics, anti-tumor activity, and recommended phase II dose/schedule of LY3164530 in patients with advanced or metastatic cancer. Patients received LY3164530 on days 1 and 15 (Schedule 1: 300, 600,
Autor:
Christian Schumann, Scott M. Hynes, Aimee Bence Lin, Martin Sebastian, Luis Paz-Ares, Klaus Dalhoff, Emiliano Calvo, Joaquim Bosch-Barrera, Ji Lin, Karla Hurt, Nicolas Dickgreber, Nuria Viñolas Segarra, Miriam Alonso, Thomas Wehler, Jesus Corral Jaime, Michael Thomas
Publikováno v:
Lung Cancer. 108:212-216
This phase 2 portion of a phase 1/2 study examined the efficacy and safety of LY2603618, a selective checkpoint kinase 1 inhibitor, combined with pemetrexed and cisplatin (LY+Pem+Cis) in patients with advanced nonsquamous non-small cell lung cancer (
Autor:
Donald A. Richards, Wu Chou Su, Scott P. Myrand, Jin Hyoung Kang, Richard K. Rosenberg, Ji Lin, Sameera R. Wijayawardana, Mary Pinder-Schenck, Scott M. Hynes, Giorgio V. Scagliotti, Aimee Bence Lin, Emily Nash Smyth, David J. Smith, Keunchil Park, Sang We Kim, Thomas E. Boyd, Silvia Novello
Publikováno v:
Investigational New Drugs. 34:625-635
Introduction LY2603618 is a selective inhibitor of checkpoint kinase 1 (CHK1) protein kinase, a key regulator of the DNA damage checkpoint, and is predicted to enhance the effects of antimetabolites, such as pemetrexed. This phase II trial assessed t
Autor:
Suzanne F. Jones, Ji Lin, Howard A. Burris, Ly M. Nguyen, Lisa Golden, Aimee Bence Lin, David S. Hong, Johanna C. Bendell, Todd M. Bauer, Aung Naing, Razelle Kurzrock, Filip Janku, Jeffrey R. Infante, Sarina Anne Piha-Paul, Faye M. Johnson, Scott M. Hynes
Publikováno v:
Journal of Clinical Oncology. 34:1764-1771
Purpose The primary objective was to determine safety, toxicity, and a recommended phase II dose regimen of LY2606368, an inhibitor of checkpoint kinase 1, as monotherapy. Patients and Methods This phase I, nonrandomized, open-label, dose-escalation
Autor:
Aimee Bence Lin, Frank Tsai, Kyriakos P. Papadopoulos, Wei Zhang, Melinda D. Willard, Amita Patnaik, Scott M. Hynes, David S. Hong, Siqing Fu, Michael Gordon, Filip Janku, Sushma R. Gundala, Drew W. Rasco, Muralidhar Beeram
Publikováno v:
Cancer Chemotherapy and Pharmacology
Purpose The phase I study characterized the safety, pharmacokinetics, anti-tumor activity, and recommended phase II dose/schedule of LY3164530 in patients with advanced or metastatic cancer. Methods Patients received LY3164530 on days 1 and 15 (Sched
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c63c0ca74ff167b4bb3706ced4921b18
https://europepmc.org/articles/PMC6829701/
https://europepmc.org/articles/PMC6829701/
Autor:
Rodney Decker, Wei Zhang, Jennifer Ott, Enaksha R Wickremsinhe, Jason Chandler, Malcolm Mitchell, Scott M. Hynes
Publikováno v:
Biopharmaceutics & Drug Disposition. 36:49-63
LY2603618 is a selective inhibitor of deoxyribonucleic acid damage checkpoint kinase 1 (CHK1) and has been in development for the enhancement of chemotherapeutic agents. The study described was to assess the potential interaction between LY2603618 an